Ventfort
Cardiovascular / VascularAlso known as: Vascular peptide complex
Mechanism
An oral peptide complex derived from blood vessel tissue. It restores endothelial function and vascular elasticity. Complementary to Vesugen (the synthetic tripeptide Lys-Glu-Asp for vessels) but derived from natural tissue extract rather than being a single synthetic sequence.
Technical detail
Peptide complex isolated from animal blood vessel tissue, containing short peptides targeting vascular endothelial and smooth muscle cells. Proposed mechanism: modulates expression of eNOS (endothelial nitric oxide synthase), elastin, collagen type III, and matrix metalloproteinases in vascular tissue. In aged animal models, improved endothelium-dependent vasodilation, reduced intima-media thickness, and normalized vascular compliance. Complementary to Vesugen (Lys-Glu-Asp), the synthetic tripeptide bioregulator for vessels. Natural extract form may contain additional peptide sequences beyond the single tripeptide. Part of Cytomax oral bioregulator series.
Effects
## Detailed Effects — Ventfort ### Vascular System [Tier 3] - Tripeptide bioregulator (Lys-Glu-Asp, same sequence as Vesugen) from the Khavinson series, designed to target vascular endothelial cells and smooth muscle. - Proposed mechanism: penetrates endothelial cell membranes and interacts with gene promoter regions to normalize expression of vascular homeostasis genes. - Proposed effects include: upregulation of eNOS (endothelial nitric oxide synthase) for improved vasodilation, normalization of VEGF expression for angiogenesis, reduction of ICAM-1 and VCAM-1 adhesion molecules (anti-inflammatory). - In vitro studies (Khavinson Institute): restoration of protein synthesis in aged vascular endothelial cell cultures, improved endothelial function markers. - Animal studies: improved microcirculation parameters, reduced arterial stiffness indices, improved wound healing (via enhanced vascularization). ### Hemostatic System [Tier 3] - Proposed normalization of coagulation balance — modulation of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) ratios. - May reduce thrombotic tendency in aging by restoring fibrinolytic capacity. ### Immune System [Tier 3] - Vascular endothelium is a key immune interface. Ventfort may reduce chronic vascular inflammation by normalizing endothelial-immune cell interactions. - Proposed reduction in leukocyte adhesion and transmigration through normalized adhesion molecule expression.
Practitioner Guide
## Practitioner Guide — Ventfort ### Clinical Context - Vascular bioregulator peptide from the Khavinson/St. Petersburg Institute series. - Not FDA-approved. Available internationally as capsules from specialized suppliers. - Used in Russian gerontology clinics for age-related vascular decline, atherosclerosis prevention, and microcirculation improvement. ### Dosing Protocols (Practitioner Consensus) - **Capsules**: 1-2 capsules daily, 15-20 minutes before meals. - **Standard course**: 30 days. Repeat every 3-6 months. - **Loading protocol**: 2 capsules BID x 10 days, then 1 capsule daily x 20 days. ### Stacking with Other Bioregulators - **Chelohart** (cardiac) + Ventfort (vascular) = comprehensive cardiovascular protocol. - **Vesugen** (also vascular, same tripeptide sequence — the distinction between Vesugen and Ventfort may be in formulation/source rather than peptide identity): practitioners may use either, but Ventfort is the more commonly cited "vessel bioregulator" in Khavinson protocols. - **Vilon** (immune) + Ventfort = vascular support with immune modulation. - **Endoluten** (pineal) + Ventfort = circadian normalization + vascular health. ### Who Uses It - Patients with early atherosclerosis or cardiovascular risk factors. - Post-MI/stroke patients (as adjunct to standard medications). - Patients with poor peripheral circulation, cold extremities, or Raynaud-like symptoms. - Longevity-focused patients in comprehensive bioregulator programs. ### Practical Tips - Best taken on an empty stomach (15-20 min before meals) for optimal absorption. - Mild enough to use alongside conventional cardiovascular medications without expected interactions (though no formal drug interaction studies exist). - Some practitioners combine Ventfort courses with cardiovascular supplements (CoQ10, omega-3, magnesium) for synergistic benefit. ### Storage - Room temperature (15-25°C). Protect from moisture and light. - Shelf life: 2-3 years for capsules. ### Monitoring - Pulse wave velocity or augmentation index (if available) for arterial stiffness. - Inflammatory markers: hsCRP, IL-6. - Lipid panel. - Subjective: energy levels, exercise tolerance, extremity warmth. ### Key Caveat - Tier 3 evidence only. No Western RCTs. - Should NOT replace statins, antihypertensives, or other evidence-based cardiovascular medications. - Use as an adjunct in patients already on appropriate standard therapy.
Research Summary
## Research Summary — Ventfort ### Tier 1: Randomized Controlled Trials - No Western RCTs available for Ventfort specifically. ### Tier 2: Preclinical & Institutional Studies - Khavinson VK et al.: in vitro studies showing tripeptide bioregulators (including the Lys-Glu-Asp sequence) interact with DNA and modulate gene expression in vascular endothelial cells. - Animal studies from St. Petersburg Institute demonstrating improved microcirculation and reduced arterial stiffness with vascular bioregulator peptides. - The broader Khavinson bioregulator program publications (~200+) provide theoretical framework but limited independent validation. ### Tier 3: Case Reports & Practitioner Protocols - 20+ years of Russian clinical use in gerontology settings. - Practitioner reports of improved peripheral circulation, reduced cold extremities, and better exercise tolerance. - Commonly combined with Chelohart in cardiovascular bioregulator protocols. - Some practitioners report improved wound healing (consistent with enhanced microcirculation). ### Gaps - No double-blind placebo-controlled RCTs in English-language literature. - No pharmacokinetic data (bioavailability, half-life, tissue distribution). - Relationship between Ventfort and Vesugen (same tripeptide sequence) is not clearly documented — may be different brands/formulations of the same peptide. - No independent replication of the claimed DNA-interaction mechanism. ### Active Trials - No registered trials on ClinicalTrials.gov. - St. Petersburg Institute continues observational and in vitro research.